Esteban Santos - 26 Feb 2026 Form 4 Insider Report for AMGEN INC (AMGN)

Role
EVP, Operations
Signature
/s/ Esteban Santos
Issuer symbol
AMGN
Transactions as of
26 Feb 2026
Net transactions value
-$11,502,452
Form type
4
Filing time
02 Mar 2026, 19:20:03 UTC
Previous filing
08 May 2025
Next filing
05 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Santos Esteban EVP, Operations ONE AMGEN CENTER DRIVE, THOUSAND OAKS /s/ Esteban Santos 27 Feb 2026 0001677950

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMGN Common Stock Options Exercise $4,959,463 +30,501 +40% $162.60 107,119 26 Feb 2026 Direct
transaction AMGN Common Stock Sale $11,563,457 -30,501 -28% $379.12 76,618 26 Feb 2026 Direct F1, F2
transaction AMGN Common Stock Options Exercise $4,310,681 +24,291 +32% $177.46 100,909 26 Feb 2026 Direct
transaction AMGN Common Stock Sale $9,209,138 -24,291 -24% $379.12 76,618 26 Feb 2026 Direct F1, F2, F3
holding AMGN Common Stock 904 26 Feb 2026 401K Plan F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMGN Nqso (Right to Buy) Options Exercise $0 -30,501 -100% $0.000000 0 26 Feb 2026 Common Stock 30,501 $162.60 Direct
transaction AMGN Nqso (Right to Buy) Options Exercise $0 -24,291 -100% $0.000000 0 26 Feb 2026 Common Stock 24,291 $177.46 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options.
F2 The price reported is an average price of $379.1173 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer
F3 These shares include 624 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
F4 These shares are acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.